Many of you know that the Phase I/II clinical trial for a potential therapy, ISIS-DMPKRx, for people with myotonic dystrophy type 1 (DM1) has been underway since last December. The trial is still actively recruiting participants. If you have DM1, are between the ages of 20-55, have no cardiac involvement and experience some grip myotonia, you may qualify to participate. Please click to access the MDF Study and Trial Resource Center or clinicaltrials.gov for more information and to communicate with specific trial sites. Questions? Contact MDF or Isis Pharmaceuticals directly.
Don't forget - good trial behavior can mean the difference between a successful clinical trial and one that fails. Click here to learn more.
[Update: Results from the Phase I/II Trial study were announced on January 5, 2017: Ionis Pharmaceuticals Reports DMPKRx Phase 1/2 Trial Results. Ionis Pharmaceuticals and Biogen also released a letter to the DM community in January 2017.]